Skip to main content
Grafa
Health
LifeMD’s $47.3 million revenue result comes with a grim forecast
Image for illustrative purposes only. Not a real photo.

LifeMD’s $47.3 million revenue result comes with a grim forecast

Share
  • LifeMD reported Q2 2026 revenue of $47.3 million and an adjusted EBITDA loss of about $3.5 million.
  • LifeMD shares fell 5.8% to $3.68 after the company lowered its full-year revenue and earnings forecasts.
  • The company is shifting patients toward longer subscriptions, branded GLP-1 therapies, pharmacy services and new healthcare partnerships.

LifeMD (NASDAQ:LFMD) reported Q2 2026 revenue of $47.3 million and cut its full-year outlook after recording a $3.5 million adjusted EBITDA loss.

Revenue declined from $49 million a year earlier, while adjusted EBITDA moved from a $3.9 million profit to a $3.5 million loss.

Gross margin rose to about 89%, active subscribers reached 356,000, and cash stood at $25.1 million with no debt.

Following the announcement, LifeMD's share price was down 5.8% at $3.68 in premarket trading.

LifeMD said about 95% of new weight-management patients now start branded GLP-1 treatments as it expands pharmacy, women’s health and XYOSTED services.

The company now forecasts 2026 revenue of $205.5 million to $212.5 million and adjusted EBITDA between a $6 million loss and breakeven.

Frequently asked questions